Over the past decade, the Steering Committee has played a central role in shaping the success of Frontiers Health and the growth of its broader health innovation ecosystem.
Novo Nordisk and Septerna have announced a global collaboration to develop oral small molecule medicines targeting obesity, type 2 diabetes, and other cardiometabolic diseases.